Matthias Löhr ʚїɞ
@maloehr.bsky.social
Professor of Gastroenterology at #Karolinska Institutet. #Pancreas lover.
🔔 Discover The Lancet Surgery & Anaesthesiology, a new journal with a sharp clinical focus, dedicated to advancing science across the full extent of #surgery, #anaesthesiology, and #perioperative specialties, across the age spectrum, and across the globe: spkl.io/633237JQbc
Who is high-risk for pancreatic cancer? Oncologist Dr. Matthew Yurgelun explains high-risk populations and what steps to take if you meet the criteria. https://bit.ly/3r82KSD
Understanding Who Is at High Risk for Pancreatic Cancer
Who is high-risk for pancreatic cancer? Oncologist Dr. Matthew Yurgelun explains high-risk populations and what steps to take if you meet the criteria.
bit.ly
This is big. The first vaccine tested to PREVENT pancreatic cancer in high-risk individuals aacrjournals.org/cancerdiscov...
First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts
Abstract. Pancreatic ductal adenocarcinoma (PDAC) arises from precursor lesions over a decade-plus, offering a window for interception in high-risk individuals, but current surveillance detects a mino...
aacrjournals.org
Pancreatic neck margin testing offers no survival benefit in pancreatic cancer surgery, highlighting need for clearer clinical guidelines. by Woo KP, Bennett WC (...) Naffouje SA et 13 al. in Ann Surg Oncol #MedSky 👉 get more here 📖 read the article:
The Practices of Pancreatic Neck Margin Testing and Their Outcomes after Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma - Annals of Surgical Oncology
Background The role of checking the pancreatic neck margin with frozen section (PNM-FS) during pancreatoduodenectomy (PD) for pancreatic ductal adenocarcinoma (PDAC) to secure R0 resection and its impact on long-term outcomes remains an area of debate. Patients and Methods Patients with PD for PDAC between 2018 and 2023 were included. The primary outcome was pancreatic neck recurrence-free survival (PN-RFS). Secondary outcomes were locoregional recurrence-free survival (LR-RFS), distant recurrence-free survival (D-RFS), and overall survival (OS). Results There were 403 patients who met inclusion criteria. PNM-FS was checked in 361 patients (89.6.2%) and returned negative at first attempt in 285 (78.9%). A total of 76 patients had positive PNM-FS; 71 were revised and clearance achieved on repeat sampling in 49 (69.0%). Median PN-RFS in patients with PNM-FS cleared with revision was significantly shorter compared with those with negative PNM-FS at first attempt (16.9 versus 23.1 months; p = 0.048) but was not different from patients with PNM-FS not cleared (16.9 versus 16.0 months; p = 0.961). LR-RFS and D-RFS were not different between the groups. OS was marginally longer in patients with negative PNM-FS at first attempt (23.9 versus 19.4 versus 16.0 months; p = 0.049). Six patients underwent completion total pancreatectomy (TP) for margin clearance, four developed distant recurrence, one locoregional recurrence and two died without disease at 1 and 11 months postoperatively. Conclusions PNM-FS is only a prognostic marker. Pursuing PNM-FS clearance does not improve PN-RFS, LR-RFS, D-RFS, or OS. Furthermore, pursuing a completion TP may be associated with shorter OS either from disease progression or surgical morbidity.
link.springer.com
🔎 Know the Symptoms of Pancreatic Cancer Losing weight without trying? Unexplained weight loss is an important warning sign that should not be ignored. Learn the 10 warning signs: https://pancreaticcancereurope.eu/wp-content/uploads/2024/04/10WS_en.pdf
A new study in Journal of Experimental & Clinical Cancer Research shows that sodium selenite can reinforce epithelial features and dampen EMT-associated plasticity in pancreatic cancer. The effect was dose- and context-dependent in patient-derived tissues. #PancreaticCancer 🧪
🎯 #FIT and #colonoscopy provide comparable #ColorectalCancer screening outcomes across sex & age groups 🔸 FIT → higher participation 🔸 Similar CRC incidence & mortality reduction 🔸 Colonoscopy detected more premalignant lesions Learn more in UEG Journal: 👉 https://bit.ly/3RDSXR0
🦠 #PancreaticCancer is linked to distinct oral & duodenal #microbiome signatures 🔸↓Duodenal microbial diversity in #PDAC 🔸Oral-duodenal taxa overlap supports microbial migration 🔸Higher salivary diversity → longer survival Access the article in UEG Journal: 👉 https://bit.ly/3RlQomF
🔎 Know the Symptoms of Pancreatic Cancer Recently diagnosed with diabetes and not sure why? In some cases, new-onset diabetes can be linked to pancreatic cancer. Learn the 10 warning signs: https://pancreaticcancereurope.eu/wp-content/uploads/2024/04/10WS_en.pdf
Morgen startet die Aktionswoche Alkohol - unterstützt durch die Stabsstelle #Krebsprävention des DKFZ. Sie lädt dazu ein, sich mit #Alkohol und Alkoholkonsum kritisch auseinanderzusetzen. Hier gibt es wissenschaftlich fundierte Informationsmaterialien: t1p.de/80guf @bdb-offiziell.bsky.social
In a phase 3 trial, obexelimab led to a lower risk of disease flares than placebo among patients with IgG4-related disease. Glucocorticoid use was lower and the incidence of remission was higher with obexelimab than with placebo. Full INDIGO trial results: https://nej.md/4fKYQG4 #EULAR2026
Daraxonrasib, the first KRAS drug for pancreatic cancer, is now available through an expanded access program, but your physician must apply for you. https://bit.ly/4uWZ9C5 #OncSky
Accessing Daraxonrasib: A Quick Primer
Daraxonrasib, the first KRAS drug for pancreatic cancer, is now available through an expanded access program.
bit.ly
Story #1 is message #1 @pancreaticcancer
NEJM.org@nejm.org · 2mo agoThree must-read studies that sparked major news coverage in May.
ICYMI: New online! Identifying MASLD patient eligibility for pharmacological therapy: the need to integrate evidence into clinical practice
Identifying MASLD patient eligibility for pharmacological therapy: the need to integrate evidence into clinical practice
Nature Reviews Gastroenterology & Hepatology, Published online: 20 May 2026; doi:10.1038/s41575-026-01214-8Metabolic dysfunction-associated steatotic liver disease is a leading cause of chronic liver disease, with rising liver transplantation rates. New therapies such as resmetirom and semaglutide mark a shift in treatment. However, identifying suitable patients remains challenging, requiring integrated approaches combining fibrosis stage, metabolic factors and non-invasive tools in real-world practice.
dlvr.it
Screening can help reverse the rising trend of digestive cancers across Europe – but only if it reaches everyone. Zorana Maravic from @digestivecancerseu.bsky.social calls for urgent action to raise awareness, increase uptake & close the access gap: https://bit.ly/4mYFleR #DigestiveHealthMonth
Did you know Gutflix has bookmarks? 🔖 Build your 'study later' list 🔖 Pick up where you left off 🔖 Save what matters to your practice Bookmark your favourite content today: https://gutflix.eu/
Demonstrating one more time the importance of the #centralorgan So-called “sympathetic” reaction
United European Gastroenterology@myueg.bsky.social · 3mo ago⚡ The #pancreas is an active player in #polytrauma Translational study (mice + 67 patients): 🔸 ↑ Pancreatic enzymes after trauma 🔸 Linked to inflammation & coagulopathy 🔸 Correlates with worse outcomes Don't miss this UEG Journal article: 👉 https://bit.ly/425dwrH
Excellent Chance to raise your Level of Expertise and increase your Network!
Pancreatic Cancer Europe@pce-europe.bsky.social · 3mo agoPCE launches the 2026 Early Career Investigator (ECI) Short-term Scientific Stay Award! 📅 Deadline: 26 June 2026 🔗 Full Call & Application Form: pancreaticcancereurope.eu/news/pce-lau...
Are you a researcher based in the USA 🇺🇸 or Canada 🇨🇦 interested in pursuing curiosity-driven research in Europe? Join the ERC and Euraxess for a webinar exploring ERC funding opportunities. 👇️ 📅 20 May 2026 🕚 11:30 AM ET | 8:30 AM PT 💻 Online Find out more and register:
ERC Grants Info Session: Funding for Excellent Frontier Research
Join EURAXESS North America and the European Research Council Executive Agency for a webinar on the bottom-up funding schemes that make up the European Research Council grants. The ERC is the premier…
buff.ly
🟣 Did you know? Your pancreas produces about 1.5 litres of digestive juices every day to help break down proteins, fats, and carbohydrates in your food. This powerful little organ is working hard behind the scenes every time you eat. 🔗 Learn more: https://pancreaticcancereurope.eu
Yesterday at the #DISCERN Annual Meeting, PCE Chairperson Alfredo Carrato joined a roundtable on patient advocacy in cancer research. The message was clear: clinical trials must meet patients where they are, emotionally and humanly. Patient voice isn't commentary, it's evidence.
Most of the work 📄 eventually being awarded with a #nobelprize was done by scientists 👩🔬 in their thirties
Nature@nature.com · 3mo agoExperienced researchers are less likely to produce ‘disruptive’ science than are those just starting their careers, finds an analysis of the scientific papers published by 12.5 million researchers over 60 years. go.nature.com/4uUvMk3
ICYMI: New online! Cirrhosis, portal hypertension and hepatocellular carcinoma: a stage-based approach
Cirrhosis, portal hypertension and hepatocellular carcinoma: a stage-based approach
Nature Reviews Gastroenterology & Hepatology, Published online: 06 May 2026; doi:10.1038/s41575-026-01209-5Cirrhosis, portal hypertension and hepatocellular carcinoma (HCC) are interconnected but are often addressed separately. This Review outlines the key interactions between portal hypertension and HCC in cirrhosis, and explores the management of these conditions across all stages, proposing an integrated, stage-based management framework.
dlvr.it
👩👧Maternal #MASLD increases risk of serious infections in offspring Swedish nationwide cohort: 🔸 Overall risk ↑ (aHR 1.81) 🔸 Highest in infancy (aHR 3.11) 🔸 Risk persists up to 31 yrs Read the article in UEG Journal: 👉 https://bit.ly/4uhhWYC
Reducing digestive cancer mortality starts even before treatment – with stronger prevention and screening. Hear from Thomas Seufferlein from ESDO on the key actions needed to move digestive cancer prevention forward 👉 https://bit.ly/4mYFleR #DigestiveHealthMonth #EUNewsline
📊 Digestive diseases and cancers place significant pressure on public health systems and economies across Europe, with findings from the White Book 2 showing that incidence, prevalence and mortality rates have been rising since 2000. Further insights in the thread below ⬇️
